We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GWW:NYSEW.W. Grainger, Inc. Analysis

Data as of 2026-04-07 - not real-time

$1,117.24

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

W.W. Grainger is trading just above its 20‑day and 50‑day moving averages at around $1,117, with the price perched between a clear support zone near $1,033 and resistance around $1,134. The stock’s RSI of 59 and a bullish MACD histogram suggest modest upside momentum, while volume has been tapering, hinting at a potential consolidation phase. Fundamentally, the company delivers an exceptional ROE of roughly 46% and a solid operating cash flow base, yet its forward PE of 23x sits modestly above the industry average of 30x, and the price‑to‑book ratio remains elevated at 14x, indicating a premium valuation. The dividend payout ratio is low at about 25% of earnings, supporting the view that the 0.8% yield is sustainable, and the beta below 1 points to lower market volatility, though the 30‑day price swing of over 22% adds a layer of short‑term risk. Recent analyst sentiment is mixed: Morgan Stanley lifted its price target to $1,190 and kept an equal‑weight rating, while the consensus recommendation remains a hold, and the market’s “Extreme Greed” sentiment reflects heightened optimism. Overall, the stock appears fairly valued with limited upside, balanced by strong profitability and cash generation, but tempered by a high valuation multiple and decreasing trading volume.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with decreasing volume
  • Bullish MACD histogram but neutral overall trend
  • Sustainable dividend despite modest yield

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Analyst target upgrades toward $1,190
  • Strong ROE and cash flow generation
  • Continued earnings growth and margin expansion

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Premium valuation multiples relative to peers
  • Stable business model with diversified geographic footprint
  • Consistent dividend policy and low leverage

Key Metrics & Analysis

Financial Health

Revenue Growth4.50%
Profit Margin9.51%
P/E Ratio31.5
ROE46.10%
ROA19.03%
Debt/Equity69.11
P/B Ratio14.2
Op. Cash Flow$2.0B
Free Cash Flow$1.1B
Industry P/E29.7

Technical Analysis

TrendNeutral
RSI59.3
Support$1,033.19
Resistance$1,133.79
MA 20$1,077.68
MA 50$1,108.99
MA 200$1,022.97
MACDBullish
VolumeDecreasing
Fear & Greed Index77.66

Valuation

Fair Value$327.48
Target Price$1,150.20
Upside/Downside2.95%
GradeFair
TypeBlend
Dividend Yield0.81%

Risk Assessment

Beta0.69
Volatility22.06%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.